1. Executive Summary
2. United States Actual Non–Invasive Prenatal Testing Volume (Number of Tests Performed) and Forecast (2015 – 2028)
2.1 Average Risk Actual NIPT Test Volume (Number of Tests Performed) and Forecast
2.2 High-Risk Actual NIPT Test Volume (Number of Tests Performed) and Forecast
3. United States Potential Non–Invasive Prenatal Testing Volume (Number of Tests Performed) and Forecast (2015 – 2028)
3.1 Average Risk Potential NIPT Test Volume (Number of Tests Performed) and Forecast
3.2 High-Risk Potential NIPT Test Volume (Number of Tests Performed) and Forecast
4. United States Actual Non–Invasive Prenatal Testing Market Size and Forecast (2015 – 2028)
4.1 Average Risk Actual NIPT Test Market Size and Forecast
4.2 High-Risk Actual NIPT Test Market Size and Forecast
5. United States Potential Non–Invasive Prenatal Testing Market Size and Forecast (2015 – 2028)
5.1 Average Risk Potential NIPT Test Market Size and Forecast
5.2 High-Risk Potential NIPT Test Market Size and Forecast
6. United States Non–Invasive Prenatal Testing Market Growth Drivers and Challenges
6.1 Key Market Growth Drivers
6.2 Key Market Challenges
7. Non–Invasive Prenatal Testing Comparative Analysis
8. Reimbursement Environment of the United States Non-Invasive Prenatal Testing Market
9. Regulation Framework of the United States Non-Invasive Prenatal Testing Market
10. Major Deals and Agreements in the Non–Invasive Prenatal Testing Market
10.1 Collaboration Deals
10.2 Venture Capital Investment
10.3 Mergers and Acquisitions
10.4 Exclusive Agreement
10.5 Licensing Agreement
10.6 Distribution Agreement
10.7 Partnership Deals
11. Key Companies Analysis
11.1 Integrated Genetics (LabCorp)
11.1.1 Business Overview
11.1.2 Product Outlook
11.1.3 Key Developments
11.2 Yourgene Health
11.2.1 Business Overview
11.2.2 Product Outlook
11.2.3 Key Developments
11.3 Ariosa Diagnostics (Roche)
11.3.1 Business Overview
11.3.2 Product Outlook
11.3.3 Key Developments
11.4 Illumina
11.4.1 Business Overview
11.4.2 Product Outlook
11.4.3 Key Developments
11.5 Natera
11.5.1 Business Overview
11.5.2 Product Outlook
11.5.3 Key Developments
11.6 Quest Diagnostics
11.6.1 Business Overview
11.6.2 Product Outlook
11.6.3 Key Developments
11.7 Myriad Genetics
11.7.1 Business Overview
11.7.2 Product Outlook
11.7.3 Key Developments
11.8 Centogene
11.8.1 Business Overview
11.8.2 Product Outlook
11.8.3 Key Developments
11.9 Invitae Corporation
11.9.1 Business Overview
11.9.2 Product Outlook
11.9.3 Key Developments
11.10 GenPath
11.10.1 Business Overview
11.10.2 Product Outlook
11.10.3 Key Developments
11.11 Progenity
9.11.1 Business Overview
11.11.1 Product Outlook
11.11.2 Key Developments
11.12 PerkinElmer
11.12.1 Business Overview
11.12.2 Product Outlook
11.12.3 Key Developments
11.13 Agilent Technologies
11.13.1 Business Overview
11.13.2 Product Outlook
11.13.3 Key Developments
Table 6–1: Maternal Age at Delivery and Risk of Down Syndrome
Table 7–1: Non–Invasive Prenatal Testing – Comparative Tests Analysis
Table 10–1: Collaboration Deals in the Non–Invasive Prenatal Testing Market
Table 10–2: Venture Capital Investment in the Non–Invasive Prenatal Testing Market
Table 10–3: Merger & Acquisition in the Non–Invasive Prenatal Testing Market
Table 10–4: Exclusive Agreement in the Non–Invasive Prenatal Testing Market
Table 10–5: Licensing Agreement in the Non–Invasive Prenatal Testing Market
Table 10–6: Distribution Agreement in the Non–Invasive Prenatal Testing Market
Table 10–7: Partnership Deals in the Non–Invasive Prenatal Testing Market
List of Figures:
Figure 2–1: United States Actual NIPT Test Volume (Thousand),2015 – 2020
Figure 2–2: United States Actual NIPT Test Volume Forecast (Thousand),2021 – 2028
Figure 2–3: United States Average Risk Actual NIPT Test Volume (Thousand),2015 – 2020
Figure 2–4: United States Average Risk Actual NIPT Test Volume Forecast (Thousand),2021 – 2028
Figure 2–5: United States High-Risk Actual NIPT Test Volume (Thousand),2015 – 2020
Figure 2–6: United States High-Risk Actual NIPT Test Volume Forecast (Thousand),2021 – 2028
Figure 3–1: United States Potential NIPT Test Volume (Thousand),2015 – 2020
Figure 3–2: United States Potential NIPT Test Volume Forecast (Thousand),2021 – 2028
Figure 3–3: United States Average Risk Potential NIPT Test Volume (Thousand),2015 – 2020
Figure 3–4: United States Average Risk Potential NIPT Test Volume Forecast (Thousand),2021 – 2028
Figure 3–5: United States High-Risk Potential NIPT Test Volume (Thousand),2015 – 2020
Figure 3–6: United States High-Risk Potential NIPT Test Volume Forecast (Thousand),2021 – 2028
Figure 4–1: United States Actual NIPT Test Market Size (Million US$),2015 – 2020
Figure 4–2: United States Actual NIPT Test Market Size Forecast (Million US$),2021 – 2028
Figure 4–3: United States Average Risk Actual NIPT Test Market Size (Million US$),2015 – 2020
Figure 4–4: United States Average Risk Actual NIPT Test Market Size Forecast (Million US$),2021 – 2028
Figure 4–5: United States High-Risk Actual NIPT Test Market Size (Million US$),2015 – 2020
Figure 4–6: United States High-Risk Actual NIPT Test Market Size Forecast (Million US$),2021 – 2028
Figure 5–1: United States Potential NIPT Test Market Size (Million US$),2015 – 2020
Figure 5–2: United States Potential NIPT Test Market Size Forecast (Million US$),2021 – 2028
Figure 5–3: United States Average Risk Potential NIPT Test Market Size (Million US$),2015 – 2020
Figure 5–4: United States Average Risk Potential NIPT Test Market Size Forecast (Million US$),2021 – 2028
Figure 5–5: United States High-Risk Potential NIPT Test Market Size (Million US$),2015 – 2020
Figure 5–6: United States High-Risk Potential NIPT Test Market Size Forecast (Million US$),2021 – 2028